Moors & Cabot Inc. Reduces Holdings in Koninklijke Philips (NYSE:PHG)

Moors & Cabot Inc. trimmed its stake in Koninklijke Philips (NYSE:PHG) by 19.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,466 shares of the technology company’s stock after selling 2,352 shares during the period. Moors & Cabot Inc.’s holdings in Koninklijke Philips were worth $240,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Koninklijke Philips in the 3rd quarter valued at $54,000. Whipplewood Advisors LLC purchased a new position in shares of Koninklijke Philips in the 4th quarter valued at $55,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Koninklijke Philips in the 3rd quarter valued at $107,000. Allworth Financial LP boosted its stake in Koninklijke Philips by 24.9% during the 4th quarter. Allworth Financial LP now owns 3,993 shares of the technology company’s stock worth $105,000 after purchasing an additional 797 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in Koninklijke Philips by 177.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,489 shares of the technology company’s stock worth $114,000 after purchasing an additional 2,871 shares during the period. 13.67% of the stock is owned by hedge funds and other institutional investors.

Koninklijke Philips Stock Up 2.5 %

PHG stock opened at $26.76 on Monday. Koninklijke Philips has a one year low of $19.10 and a one year high of $32.91. The stock has a market capitalization of $25.15 billion, a PE ratio of -31.85, a price-to-earnings-growth ratio of 0.82 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.74 and a current ratio of 1.23. The company has a fifty day moving average of $26.65 and a 200-day moving average of $27.84.

Koninklijke Philips (NYSE:PHG) last released its earnings results on Wednesday, February 19th. The technology company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.55 by ($0.01). Koninklijke Philips had a positive return on equity of 10.85% and a negative net margin of 3.88%. The firm had revenue of $5.38 billion during the quarter, compared to analyst estimates of $5.10 billion. As a group, analysts expect that Koninklijke Philips will post 1.63 EPS for the current year.

Koninklijke Philips Cuts Dividend

The business also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 13th will be paid a $0.886 dividend. This represents a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, May 13th. Koninklijke Philips’s dividend payout ratio (DPR) is -89.29%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. UBS Group upgraded shares of Koninklijke Philips from a “neutral” rating to a “buy” rating in a research note on Thursday, February 20th. StockNews.com upgraded shares of Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. Finally, BNP Paribas upgraded shares of Koninklijke Philips from a “neutral” rating to an “outperform” rating in a research note on Tuesday, February 25th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.